newsfilter
← Latest News
Business Wire·

CytRx Highlights Preliminary Results of Cohort C of QUILT 88, a Phase 2 Pancreatic Cancer Trial That Includes Aldoxorubicin, Expected to be Released in Q1 2022

ImmunityBio's Receipt of U.S. Patent for Novel Immunotherapy, NANT Cancer Vaccine, Being Studied in Multiple Clinical Trials CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and de